FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Foghorn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.87+0.02 (+1.08%)
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.12 (−53.13%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Foghorn Therapeutics Inc. grew revenue 52.0% to $36.74M over the twelve months to Jun 30, 2026. Free cash flow was -$84.29M.
Revenue
$36.74M
+52.0% vs. a year earlier
Operating income
-$72.76M
TTM Q2 2026
Free cash flow
-$84.29M
TTM Q2 2026
EPS, diluted
-$0.98
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $132.08M
- P/E ratio
- –
- Price to sales
- 3.60
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -63.82%
Fundamentals
- Revenue
- $36.74M
- Net income
- -$64.58M
- EPS, diluted
- -$0.98
- Free cash flow
- -$84.29M
- Book value per share
- -$1.15
- Diluted shares
- 71M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$36.74M+52.0% YoY
Operating income
-$72.76M
Net income
-$64.58M
EPS, diluted
-$0.98
Free cash flow
-$84.29M
Reported periodTrailing twelve months